Clinical trial
An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).
NCT00421811 is registered in ClinicalTrials.gov with Adherex Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).
- Lead sponsor
- Adherex Technologies, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 30, 2007
- Completion date
- March 31, 2009
- Enrollment
- 56 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.